Stephens Consulting, LLC Rhythm Pharmaceuticals, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 20 shares of RYTM stock, worth $1,234. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$1,234% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RYTM
# of Institutions
219Shares Held
64.5MCall Options Held
445KPut Options Held
26.6K-
Black Rock Inc. New York, NY6.74MShares$416 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA6.57MShares$406 Million0.29% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$376 Million5.51% of portfolio
-
Baker Bros. Advisors LP New York, NY6.08MShares$376 Million3.77% of portfolio
-
Perceptive Advisors LLC New York, NY3.68MShares$227 Million6.86% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.44B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...